Abstract Objective To study the clinical effect and mechanism of hemoperfusion (HP) in the treatment of children with severe abdominal Henoch-Schönlein purpura (HSP). Methods A total of 24 children with severe abdominal HSP were divided into two groups:conventional treatment and HP (n=12 each). Ten healthy children who underwent physical examination were enrolled as the control group. Before and after treatment, chemiluminescence was used to measure the serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α); thiobarbituric acid colorimetry was used to measure the plasma level of malondialdehyde (MDA); the hydroxylamine method was used to measure the plasma level of superoxide dismutase (SOD); chemical colorimetry was used to measure the plasma level of total anti-oxidant capability (T-AOC). Results Compared with the control group, the conventional treatment and HP groups had significantly higher IL-6, TNF-α, and MDA levels and significantly lower SOD and T-AOC levels before treatment (P < 0.05), but there were no significant differences between the conventional treatment and HP groups (P > 0.05). After treatment, the conventional treatment and HP groups had significant reductions in IL-6, TNF-α, and MDA levels and significant increases in SOD and T-AOC levels (P < 0.05). The HP group had significantly greater changes than the conventional treatment group; however, there were still significant differences in these indices between the HP and control groups (P < 0.05). Compared with the HP group, the conventional treatment group had a significantly lower percentage of children with disappearance of digestive tract symptoms at 4 days after treatment and significantly longer time to disappearance of rash and digestive tract symptoms (P < 0.05). Compared with the conventional treatment group, the HP group had a significantly lower amount of glucocorticoid used during treatment and a significantly lower percentage of children who experienced hematuria and/or proteinuria within 6 months of the disease course (P < 0.05). There were no significant differences between the two groups in length of hospital stay and recurrence rates of rash and abdominal pain within 6 months of the disease course. Conclusions HP can reduce the amount of glucocorticoid used during treatment and the incidence rate of kidney injury in children with severe abdominal HSP, possibly by eliminating IL-6, TNF-α, and MDA.
ZHU Ying,DONG Yang,XU Da-Liang et al. Clinical effect and mechanism of hemoperfusion in treatment of children with severe abdominal Henoch-Schönlein purpura[J]. CJCP, 2018, 20(5): 378-382.
ZHU Ying,DONG Yang,XU Da-Liang et al. Clinical effect and mechanism of hemoperfusion in treatment of children with severe abdominal Henoch-Schönlein purpura[J]. CJCP, 2018, 20(5): 378-382.
Başaran Ö, Cakar N, Uncu N, et al. Plasma exchange therapy for severe gastrointestinal involvement of Henoch Schönlein purpura in children[J]. Clin Exp Rheumatol, 2015, 33(Suppl 89):S176-S180.
Kimura S, Takeuchi S, Soma Y, et al. Raised serum levels of interleukins 6 and 8 and antiphospholipid antibodies in an adult patient with Henoch-Schönlein purpura[J]. Clin Exp Dermatol, 2013, 38(7):730-736.
[8]
Sedaghat Z, Kadkhodaee M, Seifi B, et al. Hind limb preconditioning renoprotection by modulation of inflammatory cytokines after renal ischemia/reperfusion[J]. Ren Fail, 2016, 38(5):655-662.
Ma DQ, Li Y, Han ZG, et al. Analysis on kidney injury-related clinical risk factors and evaluation on the therapeutic effects of hemoperfusion in children with Henoch-Schönlein purpura[J]. Eur Rev Med Pharmacol Sci, 2017, 21(17):3894-3899.
